In addition, Dupilumab, a monoclonal antibody against IL-4 receptor α, significantly suppressed the expression of Th2-type chemokines (CCL17, CCL18, CCL22, and CCL26) and had been approved by FDA for the therapy of moderate-to-severe AD in adult patients [39]. This evidence concerns the gene CCL22 and Alzheimer disease.